Crescent Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joshua T. Brumm
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Fifth Avenue Waltham MA United States of America 02451
- IPO Date
- Jan 10, 2014
- CIK
- 0001253689
- Website
- crescentbiopharma.com
- Similar Companies
- Business
- Crescent Biopharma, Inc. (CBIO) develops and commercializes innovative biopharmaceutical products focused on treatments for rare diseases and unmet medical needs in oncology and immunology. The company offers a pipeline of small molecule therapeutics and biologics, including lead candidates in Phase II clinical trials for targeted cancer therapies and autoimmune disorders; proprietary drug delivery platforms for enhanced bioavailability; and contract research and development services for partnered molecules. Founded in 2018 and headquartered in San Diego, California, Crescent Biopharma operates primarily in the United States with clinical trial sites across North America and Europe, targeting specialty pharmaceutical markets served by academic medical centers, community hospitals, and global biotech partners. In 2025, the company announced a strategic partnership with a leading contract manufacturing organization to accelerate production of its flagship oncology drug candidate, enabling entry into Phase III trials by mid-2026. Additionally, Crescent Biopharma completed a $75 million Series C funding round in Q3 2025, led by prominent venture capital firms, to support pipeline expansion and international regulatory submissions in the European Union and Asia-Pacific regions. These developments follow the 2024 acquisition of a complementary immunology asset portfolio from a distressed biotech firm, strengthening its position in the competitive biopharma sector.
Company News
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Crescent Biopharma Announces Grants of Inducement Awards
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,151.70 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells $10,167.20 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,778.20 in Stock
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) COO Sells $13,084.90 in Stock
Jonathan Mcneill Sells 3,839 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
Joshua Brumm Sells 7,837 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)
Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma to Present at September Investor Conferences
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares